Basic fibroblast growth factor in retardation of doxorubicin extravasation injury.
Extravasation of chemotherapeutic agents such as doxorubicin results in significant morbidity and remains a serious clinical problem. No single agent or combination of agents has proven to be completely effective in preventing the chronic avascular ulcerative wound. Basic fibroblast growth factor (bFGF) is one of many angiogenic agents and is strongly mitogenic for vascular endothelial cells in nanogram quantities. In a Sprague-Dawley rat model, bFGF was moderately effective in retarding the development of doxorubicin-induced skin ulceration.
Vasilev
S A
SA
Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles 90033.
Morrow
C
C
Morrow
C P
CP
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002908:Chronic Disease; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D013997:Time Factors
D016222:Fibroblast Growth Factor 2; D004317:Doxorubicin